• Organon will present a pooled post-hoc analysis of Phase 3 VTAMA cream trials at ACAAI on Nov. 14, 2026.
• The trials enrolled 813 adults and children aged 2 and older with moderate to severe atopic dermatitis.
• VTAMA improved disease severity and itch versus vehicle across evaluated patient subgroups, with benefits appearing within one week and lasting through eight weeks.
• The nonsteroidal topical treatment was well tolerated; common adverse events included folliculitis, headache and respiratory infections.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261112109975) on November 12, 2026, and is solely responsible for the information contained therein.